Abstract
The gold standard surgical treatment for heart failure is cardiac transplantation, however, due to difficulties of this treatment, other surgical proposals have been reported, including the implantation of cardiac resynchronizer. To analyze the left ventricular function by echocardiography in patients with advanced heart failure with interventricular dyssynchrony undergone implantation of cardiac resynchronizer. Between June 2006 and June 2012, 24 patients with average age of 61.5 ± 11 years were evaluated, carriers of advanced congestive heart failure functional class III and IV (NYHA), interventricular dyssynchrony and optimal drug therapy, and submitted implantation of cardiac resynchronizer and postoperative echocardiographically evaluated in six months. There was significant improvement of the analyzed echocardiography parameters. The average left ventricular diastolic diameter decreased from 69.6 ± 9.8 mm to 66.8 ± 8.8 mm, systolic diameters from 58.6 ± 8.8 mm to 52.7 ± 8.8 mm, and ejection fraction, average of 31 ± 8% to 40 ± 7% with level of significance, respectively, of 0.019, 0.0004 and 0.0002, statistically significant with a significance level of 0.05. There was a significant improvement of left ventricular function analyzed by echocardiography at six months, in patients with advanced heart failure undergone implantation of cardiac resynchronizer.
Highlights
Heart failure (HF) one of the greatest clinical challenges in the current public health, and it is considered an epidemic on progress, diagnosed in 1% to 2% of developed countries population [1,2].The HF is one of the most prevalent causes of hospital admissions in Brazil, on the Unified Health System (SUS)
There was a significant improvement of left ventricular function analyzed by echocardiography at six months, in patients with advanced heart failure undergone implantation of cardiac resynchronizer
Casuistry The echocardiographic data of 24 patients with severe congestive heart failure were analyzed, classified as NYHA functional class III and IV according to the Criteria Committee of the NYHA, underwent implantation of transvenous cardiac resynchronizer, by Cardiovascular Surgery Service of the discipline of Cardiothoracic Surgery of the Helio Mandetta Faculty of MedicineFederal University of Mato Grosso do Sul (UFMS), between June 2006 to June 2012, with the approval of the UFMS Ethics Committee in humans in the approval letter - protocol number 2235-CAAE 0354.0.049.000 11, on November 9, 2011
Summary
Heart failure (HF) one of the greatest clinical challenges in the current public health, and it is considered an epidemic on progress, diagnosed in 1% to 2% of developed countries population [1,2]. The HF is one of the most prevalent causes of hospital admissions in Brazil, on the Unified Health System (SUS). The HF treatment has the purpose of symptoms improvement, reduction of mortality, hospital costs decreasing and prevention of readmissions. The treatment of heart failure consists of: nonpharmacological steps (diet, exercising, stress management, and others), drug therapy and surgery [3]. The gold standard surgical treatment for heart failure is cardiac transplantation, due to difficulties of this treatment, other surgical proposals have been reported, including the implantation of cardiac resynchronizer
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
